Using qualitative methods to establish the clinically meaningful threshold for treatment success in alopecia areata

Men's baldness stigma: A mixed methods international survey

Men's baldness can be structurally stigmatized. For example, commercialized psychology research medicalizes it as a distressing "disease." A mixed-methods survey on baldness stigma among 357 balding men (49% from Central- and South- America, Africa, Asia) was conducted. Qualitative and quantitative responses were content analyzed into two approximate sets: those (1) impacted by baldness stigma versus (2) those resisting baldness stigma. (1) The former included about half who had internalized baldness stigma agreeing it was disadvantageous (44%) and reporting distress (39-45% e.g. "[I] dread the future"). Participants reported baldness was stigmatized structurally (68%; e.g. "[it's a] humiliating image") and were attempting to combat their baldness largely via "treatments" (57%). (2) The latter participant response set resisted baldness stigma by reporting minimal distress, and structural stigma whilst accepting baldness (33-61%). Psychosocial and evidence-based support is needed to help some men resist baldness stigmatization.

The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta-analyses of clinical trials

BACKGROUND

Janus kinase (JAK) inhibitors, biologics, and phosphodiesterase-4 (PDE-4) inhibitors are recent therapies for alopecia areata (AA)-albeit, knowledge gaps exist for these agents' relative efficacy.

OBJECTIVES

We determined the relative efficacy and safety of monotherapy with the aforementioned agents in adults with AA.

METHODS

The literature was systematically searched; we used data from randomized trials that investigated the agents' efficacy-as per Severity of Alopecia Tool (SALT) scores. Bayesian network meta-analyses were used to determine relative efficacy and safety. Effect modification was determined using a generalized linear model on aggregate data; evidence quality was evaluated.

RESULTS

Based on the surface under the cumulative ranking curve estimates obtained from multiple efficacy endpoints, regimens with the highest likelihood of achieving percent reduction in SALT scores, as well as a minimum 90%, 75% or 50% reduction in SALT scores are (in alphabetical order) baricitinib 4 mg once daily (QD), brepocitinib 60/30 mg QD, deuruxolitinib (CTP-543) 12 mg twice daily (BID), ritlecitinib 200/50 mg QD, ruxolitinib 20 mg BID and tofacitinib 5 mg BID. In contrast, dupilumab subcutaneous injections administered weekly and apremilast 30 mg BID were less likely to be effective. Discontinuation due to any adverse event was the least likely with oral JAK inhibitors, and more likely with dupilumab and apremilast.

CONCLUSIONS

Our results support the conduct of high-quality comparative trials to determine whether JAK inhibitors are more effective and safer than PDE4 inhibitors.